Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Medical Oncologists' Views on the Utility of Medical Marijuana Across the Cancer Trajectory.

Braun IM, Blonquist TM, Campbell EG, Nayak MM, Bolcic-Jankovic D, Wright AA.

J Pain Symptom Manage. 2019 Jun;57(6):e1-e4. doi: 10.1016/j.jpainsymman.2019.02.001. Epub 2019 Feb 19. No abstract available.

PMID:
30794936
2.

The effect of a lifestyle risk reduction intervention on lifestyle adherence and health-related quality of life in nonsmall cell lung cancer survivors: Feasibility study outcomes.

Cooley ME, Blonquist TM, Hong F, Nayak MM, Crouter SE, Hayman LL, Jaklitsch MT, Emmons KM, Bueno R.

Psychooncology. 2019 Apr;28(4):920-923. doi: 10.1002/pon.5002. Epub 2019 Feb 12. No abstract available.

PMID:
30673155
3.

Assigning value to preparation for prostate cancer decision making: a willingness to pay analysis.

Wilson LS, Blonquist TM, Hong F, Halpenny B, Wolpin S, Chang P, Filson CP, Master VA, Sanda MG, Chien GW, Jones RA, Krupski TL, Berry DL.

BMC Med Inform Decis Mak. 2019 Jan 9;19(1):6. doi: 10.1186/s12911-018-0725-4.

4.

A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer.

Shulman DS, Mehrotra P, Blonquist TM, Capraro A, Lehmann LE, Silverman LB, Surana NK, Place AE.

Pediatr Blood Cancer. 2019 Apr;66(4):e27568. doi: 10.1002/pbc.27568. Epub 2018 Dec 11.

PMID:
30537106
5.

Self-Care Support for Patients with Gastrointestinal Cancer: iCancerHealth.

Berry DL, Blonquist TM, Nayak MM, Grenon N, Momani TG, McCleary NJ.

Appl Clin Inform. 2018 Oct;9(4):833-840. doi: 10.1055/s-0038-1675810. Epub 2018 Nov 21.

PMID:
30463094
6.

Understanding health decision making: An exploration of homophily.

Berry DL, Blonquist TM, Pozzar R, Nayak MM.

Soc Sci Med. 2018 Oct;214:118-124. doi: 10.1016/j.socscimed.2018.08.026. Epub 2018 Aug 24. Review.

PMID:
30172920
7.

Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.

Vrooman LM, Blonquist TM, Harris MH, Stevenson KE, Place AE, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB.

Blood Adv. 2018 Jun 26;2(12):1449-1458. doi: 10.1182/bloodadvances.2018016584.

8.

Reply to comment on: Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.

Sulis ML, Blonquist TM, Stevenson KE, Hunt SK, Kay-Green S, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JG, Neuberg DS, Sallan SE, Silverman LB.

Pediatr Blood Cancer. 2018 Aug;65(8):e27082. doi: 10.1002/pbc.27082. Epub 2018 Apr 25. No abstract available.

PMID:
29693795
9.

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.

Tran TH, Harris MH, Nguyen JV, Blonquist TM, Stevenson KE, Stonerock E, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJG, Reshmi SC, Neuberg DS, Sallan SE, Loh ML, Silverman LB.

Blood Adv. 2018 Mar 13;2(5):529-533. doi: 10.1182/bloodadvances.2017014704.

10.

Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities.

Weinberg OK, Gibson CJ, Blonquist TM, Neuberg D, Pozdnyakova O, Kuo F, Ebert BL, Hasserjian RP.

Haematologica. 2018 Apr;103(4):626-633. doi: 10.3324/haematol.2017.181842. Epub 2018 Jan 11.

11.

Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.

Sulis ML, Blonquist TM, Stevenson KE, Hunt SK, Kay-Green S, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JG, Neuberg DS, Sallan SE, Silverman LB.

Pediatr Blood Cancer. 2018 May;65(5):e26952. doi: 10.1002/pbc.26952. Epub 2018 Jan 10.

PMID:
29319209
12.

Risk and timing of cardiovascular death among patients with myelodysplastic syndromes.

Brunner AM, Blonquist TM, Hobbs GS, Amrein PC, Neuberg DS, Steensma DP, Abel GA, Fathi AT.

Blood Adv. 2017 Oct 18;1(23):2032-2040. doi: 10.1182/bloodadvances.2017010165. eCollection 2017 Oct 24.

13.

An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001.

Kahn JM, Cole PD, Blonquist TM, Stevenson K, Jin Z, Barrera S, Davila R, Roberts E, Neuberg DS, Athale UH, Clavell LA, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJG, Sallan SE, Silverman LB, Kelly KM.

Pediatr Blood Cancer. 2018 Mar;65(3). doi: 10.1002/pbc.26871. Epub 2017 Nov 1.

14.

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.

Fathi AT, Blonquist TM, Hernandez D, Amrein PC, Ballen KK, McMasters M, Avigan DE, Joyce R, Logan EK, Hobbs G, Brunner AM, Joseph C, Perry AM, Burke M, Behnan T, Foster J, Bergeron MK, Moran JA, Ramos AY, Som TT, Rae J, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Levis MJ.

Cancer. 2018 Jan 15;124(2):306-314. doi: 10.1002/cncr.31038. Epub 2017 Sep 28. Erratum in: Cancer. 2018 May 15;124(10 ):2258.

15.

Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial.

Berry DL, Hong F, Blonquist TM, Halpenny B, Filson CP, Master VA, Sanda MG, Chang P, Chien GW, Jones RA, Krupski TL, Wolpin S, Wilson L, Hayes JH, Trinh QD, Sokoloff M, Somayaji P.

J Urol. 2018 Jan;199(1):89-97. doi: 10.1016/j.juro.2017.07.076. Epub 2017 Jul 25.

16.

A state-wide initiative to promote genetic testing in an underserved population.

Underhill ML, Blonquist TM, Habin K, Lundquist D, Shannon K, Robinson K, Woodford ML, Boucher J.

Cancer Med. 2017 Jul;6(7):1837-1844. doi: 10.1002/cam4.1100. Epub 2017 May 29.

17.

Feasibility and acceptability of "healthy directions" a lifestyle intervention for adults with lung cancer.

Blok AC, Blonquist TM, Nayak MM, Somayaji D, Crouter SE, Hayman LL, Colson YL, Bueno R, Emmons KM, Cooley ME.

Psychooncology. 2018 Jan;27(1):250-257. doi: 10.1002/pon.4443. Epub 2017 May 31.

PMID:
28426922
18.

NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification.

Weinberg OK, Gibson CJ, Blonquist TM, Neuberg D, Pozdnyakova O, Kuo F, Ebert BL, Hasserjian RP.

Am J Hematol. 2017 Jul;92(7):E123-E124. doi: 10.1002/ajh.24739. Epub 2017 May 26. No abstract available.

19.

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.

Fathi AT, Wander SA, Blonquist TM, Brunner AM, Amrein PC, Supko J, Hermance NM, Manning AL, Sadrzadeh H, Ballen KK, Attar EC, Graubert TA, Hobbs G, Joseph C, Perry AM, Burke M, Silver R, Foster J, Bergeron M, Ramos AY, Som TT, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Chen YB.

Haematologica. 2017 Apr;102(4):719-727. doi: 10.3324/haematol.2016.158394. Epub 2016 Dec 29.

20.

A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia.

Finkelstein Y, Blonquist TM, Vijayanathan V, Stevenson KE, Neuberg DS, Silverman LB, Vrooman LM, Sallan SE, Cole PD.

Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26393. Epub 2016 Dec 13.

PMID:
27957785
21.

Patient-reported symptom distress, and most bothersome issues, before and during cancer treatment.

Hong F, Blonquist TM, Halpenny B, Berry DL.

Patient Relat Outcome Meas. 2016 Sep 12;7:127-35. doi: 10.2147/PROM.S95593. eCollection 2016.

22.

Psychosocial outcomes of an electronic self-report assessment and self-care intervention for patients with cancer: a randomized controlled trial.

Fann JR, Hong F, Halpenny B, Blonquist TM, Berry DL.

Psychooncology. 2017 Nov;26(11):1866-1871. doi: 10.1002/pon.4250. Epub 2016 Sep 15.

23.

Impact of Socioeconomic Status on Timing of Relapse and Overall Survival for Children Treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000-2010).

Bona K, Blonquist TM, Neuberg DS, Silverman LB, Wolfe J.

Pediatr Blood Cancer. 2016 Jun;63(6):1012-8. doi: 10.1002/pbc.25928. Epub 2016 Feb 23.

PMID:
26913850
24.

Self-reported adherence to oral cancer therapy: relationships with symptom distress, depression, and personal characteristics.

Berry DL, Blonquist TM, Hong F, Halpenny B, Partridge AH.

Patient Prefer Adherence. 2015 Nov 4;9:1587-92. doi: 10.2147/PPA.S91534. eCollection 2015.

25.

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB.

Lancet Oncol. 2015 Dec;16(16):1677-90. doi: 10.1016/S1470-2045(15)00363-0. Epub 2015 Nov 6.

PMID:
26549586
26.

Screening for Pain in the Ambulatory Cancer Setting: Is 0-10 Enough?

LeBaron VT, Blonquist TM, Hong F, Halpenny B, Berry DL.

J Oncol Pract. 2015 Nov;11(6):435-41. doi: 10.1200/JOP.2015.004077. Epub 2015 Aug 25.

27.

Exposure to a patient-centered, Web-based intervention for managing cancer symptom and quality of life issues: impact on symptom distress.

Berry DL, Blonquist TM, Patel RA, Halpenny B, McReynolds J.

J Med Internet Res. 2015 Jun 3;17(6):e136. doi: 10.2196/jmir.4190.

28.

Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia.

Cole PD, Finkelstein Y, Stevenson KE, Blonquist TM, Vijayanathan V, Silverman LB, Neuberg DS, Sallan SE, Robaey P, Waber DP.

J Clin Oncol. 2015 Jul 1;33(19):2205-11. doi: 10.1200/JCO.2014.59.0273. Epub 2015 May 18.

29.

Patient cues and symptoms of psychosocial distress: what predicts assessment and treatment of distress by oncology clinicians?

Sheldon LK, Blonquist TM, Hilaire DM, Hong F, Berry DL.

Psychooncology. 2015 Sep;24(9):1020-7. doi: 10.1002/pon.3689. Epub 2014 Oct 7.

PMID:
25288344
30.

Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis.

Movassaghian M, Brunner AM, Blonquist TM, Sadrzadeh H, Bhatia A, Perry AM, Attar EC, Amrein PC, Ballen KK, Neuberg DS, Fathi AT.

Leuk Lymphoma. 2015 Jun;56(6):1698-703. doi: 10.3109/10428194.2014.963080. Epub 2014 Oct 9.

PMID:
25213180
31.

Feasibility of using algorithm-based clinical decision support for symptom assessment and management in lung cancer.

Cooley ME, Blonquist TM, Catalano PJ, Lobach DF, Halpenny B, McCorkle R, Johns EB, Braun IM, Rabin MS, Mataoui FZ, Finn K, Berry DL, Abrahm JL.

J Pain Symptom Manage. 2015 Jan;49(1):13-26. doi: 10.1016/j.jpainsymman.2014.05.003. Epub 2014 May 29.

32.

Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis.

Brunner AM, Blonquist TM, Sadrzadeh H, Perry AM, Attar EC, Amrein PC, Ballen KK, Chen YB, Neuberg DS, Fathi AT.

Leuk Res. 2014 Jul;38(7):773-80. doi: 10.1016/j.leukres.2014.04.001. Epub 2014 Apr 12.

Supplemental Content

Loading ...
Support Center